Key takeaways
Rybelsus (semaglutide) and Mounjaro (tirzepatide) are both medications used to treat type 2 diabetes, but they belong to different classes. Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist, while Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Rybelsus is taken orally once a day, whereas Mounjaro is injected under the skin once a week. Both medications are only available as a brand-name products. Both Rybelsus and Mounjaro can cause side effects like nausea, vomiting, and diarrhea, and have a warning about the risk of thyroid tumors or cancer. Mounjaro is the first medication in its class and can lower hemoglobin A1C levels more than Rybelsus. Both medications can interact with other diabetes medications, potentially causing low blood sugar, so it's important to monitor your blood sugar levels closely.
